Skip to main
NUVL

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 16%
Buy 32%
Hold 53%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent is a promising clinical-stage biopharmaceutical company with a strong pipeline of product candidates focused on addressing the limitations of existing cancer therapies. Its lead asset, zidesamtinib, has demonstrated impressive clinical results in ROS1-positive NSCLC and has received FDA approval for submission. The recent acquisition by GSK further enhances Nuvalent's global commercial outlook and brings in a strong partner with a global platform and minimal regulatory risk. The risks to the company's current valuation and price target include potential negative clinical results and competition from other products, as well as regulatory and commercial risks. Despite these risks, Nuvalent's strong pipeline and partnership with GSK make it a promising investment opportunity.

Bears say

Nuvalent is a clinical-stage biopharmaceutical company with a portfolio of potential best-in-class kinase inhibitors targeting clinically validated oncogenic drivers, including zidesamtinib and neladalkib. However, despite having promising assets, the company is not yet generating revenue and requires significant capital to complete development, posing a financial risk. Additionally, the recent acquisition offer from GlaxoSmithKline at a 40% premium to Nuvalent's closing price may indicate that there is limited potential for a competing bid, signaling a lack of interest from other major players in the industry.

Nuvalent (NUVL) has been analyzed by 19 analysts, with a consensus rating of Buy. 16% of analysts recommend a Strong Buy, 32% recommend Buy, 53% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 19 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $129.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $129.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.